Richard LeBlanc
0000-0001-9990-2183
8 papers found
Refreshing results…
Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed and Refractory Multiple Myeloma
Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study
Newly diagnosed multiple myeloma patients treated with tandem auto‐allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only
Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: A multicenter retrospective study.
Missing publications? Search for publications with a matching author name.